ClinicalTrials.gg
CompletedNCT05817669rhoUpdated Jul 18, 2025Results posted

A Study of the Safety and Effectiveness of Efgartigimod in Patients With Primary Sjögren's Syndrome (pSS)

A Phase 2 interventional study of Efgartigimod and Placebo in Primary Sjögren's Syndrome, sponsored by argenx. Completed at 17 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-18.

Sponsored by argenx · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
34
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to assess the efficacy and safety of human FcRn blocking therapy with efgartigimod compared to placebo, in participants with pSS.

Read the detailed description

Primary Sjogren Syndrome (pSS) is an autoimmune disease with still unmet treatment needs. Efgartigimod, a human FcRn antagonist, has the potential to successfully treat pSS and improve disease manifestations by the reduction of IgG autoantibodies and immune complexes in pSS. The study design is randomized, double-blinded, and placebo-controlled to evaluate the effect of efgartigimod administered as an IV infusion compared to placebo. The study consists of a treatment period when all participants will receive infusions of IP/placebo for 24 weeks. At the end of the randomized treatment period, eligible participants may roll over to an OLE study or remain in this study through the end of the 56-day follow-up period.

02

Conditions studied

  • Primary Sjögren's Syndrome
03

In context

Lead sponsor

argenx is the lead sponsor of 87 studies on the registry; 28 are open to participants now.

Of its 22 completed or terminated interventional studies of FDA-regulated products, 16 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Is at least the legal age of consent for clinical trials when signing the form
  • Is capable of providing signed informed consent and complying with protocol requirements
  • Agrees to use measures consistent with local regulations and measures described in the protocol
  • Meets the following criteria at screening: ACR/EULAR 2016 pSS who met criteria ≤7 years before screening; ESSDAI ≥5; Anti-Ro/SS-A positive; Residual salivary flow (UWSF rate >0 and/or SWSF rate >0.10)

Exclusion criteria

Exclusion Criteria:

  • Known disease or any medical condition that, in the investigator's judgment,would interfere with an accurate assessment of clinical symptoms of pSS or puts the participant at undue risk
  • History of unless considered cured by adequate treatment with no evidence of recurrence for ≥3 years before the first administration of IMP.
  • Adequately treated participants with the following cancers may be included at any time: Basal cell or squamous cell skin cancer; Carcinoma in situ of the cervix; Carcinoma in situ of the breast; Incidental histological finding of prostate cancer (TNM stage T1a or T1b) uncontrolled active acute or chronic bacterial, viral, or fungal infection
  • Positive serum test at screening for an active infection with any of the following: that is indicative of an acute or chronic infection, unless associated with a negative HBsAg or negative HBV DNA test; based on HCV antibody assay unless a negative RNA test is available; based on test results of a of \<200 cells/mm3 that are associated with an AIDS-defining condition, HIV based on test results of a CD4 count of >200 cells/mm3 not adequately treated with antiviral therapy
  • Clinically significant disease, recent major surgery (within 3 months of screening), or intention to have surgery during the study; or any other medical condition that, in the investigator's opinion, would confound the results of the study or put the participant at undue risk
  • Immunoglobulin G (IgG) levels cannot be below a certain threshold ( 4g/L)
  • Positive covid test at study start
  • Some of the medications such as vaccines with live components or medicines that may be prescribed cannot be taken either shortly before or during this study
  • Current participation in another interventional clinical study or previously participation in an efgartigimod clinical study and treatment with ≥1 dose of IMP
  • Known to IMP or 1 of its
  • History (within 12 months of screening) of current alcohol, drug, or medication abuse as assessed by the investigator
  • Pregnant or lactating state or intention to become pregnant during the study
  • Secondary Sjögren's syndrome overlap syndromes where another confirmed autoimmune rheumatic or systemic inflammatory condition is the primary diagnosis
  • Chinese traditional medicine with known immunomodulatory action
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
34 participants (actual)

Study arms

  • Experimental
    Efgartigimod IV arm

    patients receiving infusions of Efgartigimod IV

    Biological: Efgartigimod

  • Placebo comparator
    Placebo arm

    patients receiving infusions of placebo IV

    Biological: Placebo

Interventions

  • BiologicalEfgartigimod

    Patients receiving efgartigimod infusions

  • BiologicalPlacebo

    Patients receiving placebo infusions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Meeting Overall CRESS Response of at Least 3 of 5 Items at Week 24

    A Composite of Relevant Endpoints for Sjögren's Syndrome (CRESS) responder is defined as improvements in at least 3 of the 5 items of CRESS (systemic disease activity, patient-reported symptoms, tear gland function, salivary gland function and serology. The score ranges from 0 to 9 (higher score = worse symptoms).

    Time frame: Week 24

Secondary outcomes

  1. Number of Participants With TEAEs, AESI, and SAEs

    A treatment-emergent adverse event (TEAE): adverse events reported from the first dose up to and including 60 days after the final dose were considered treatment-emergent. Serious adverse event (SAE): adverse event that resulted in death, was life threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect or other situations. Adverse event of special interest (AESI): adverse event related to 'Infections and infestations'.

    Time frame: Up to 32 weeks

  2. Percentage of Participants With MCII in ESSDAI at Week 24

    European Alliance of Associations for Rheumatology (EULAR) Sjögren's Syndrome Disease Activity Index (ESSDAI) measures systemic disease activity in participants with pSjD and consists of 11 organ-specific domains and 1 biological domain that contribute to disease activity level scoring. Each domain is given a certain weight, which gives a score between 0 and 123 (higher score =worse symptoms). Minimally clinically important improvement (MCII) in ESSDAI was defined as improvement of at least 3 points in ESSDAI score at Week 24.

    Time frame: Week 24

  3. Percentage of Participants With Low Disease Activity in ESSDAI at Week 24

    ESSDAI measures systemic disease activity in participants with pSjD and consists of 11 organ-specific domains and 1 biological domain that contribute to disease activity level scoring. Each domain is given a certain weight, which gives a score between 0 and 123 (higher score =worse symptoms). Low disease activity in ESSDAI was defined as ESSDAI score of less than 5 at Week 24.

    Time frame: Week 24

  4. Percentage of Participants With MCII in clinESSDAI at Week 24

    Clinical (clin)ESSDAI includes the same 11 organ-specific domains as ESSDAI but with different domain weighting and without the biological domain. This way any change in clinESSDAI score would reflect disease specific features, irrespective of B-cell activity. The clinESSDAI score ranges between 0-135 (higher score = worse symptoms). Minimal clinically important improvement (MCII) in clinESSDAI was defined as improvement of at least 3 points in clinESSDAI score at Week 24.

    Time frame: Week 24

  5. Percentage of Participants With Low Disease Activity in clinESSDAI at Week 24

    clinESSDAI includes the same 11 organ-specific domains as ESSDAI but with different domain weighting and without the biological domain. This way any change in clinESSDAI score would reflect disease specific features, irrespective of B-cell activity. The clinESSDAI score ranges between 0-135 (higher score = worse symptoms). Low disease activity in clinESSDAI was defined as clinESSDAI score of less than 5 at Week 24.

    Time frame: Week 24

  6. Percentage of Participants With MCII in ESSPRI at Week 24

    Minimal clinically important improvement in ESSPRI was defined as decrease of 1 point or at least ≥15% at Week 24. ESSPRI is a questionnaire that has been developed to measure self-reported symptoms in participants with pSjD. The score ranges from 0 (no symptoms) to 10 (more symptoms).

    Time frame: Week 24

  7. Change From Baseline in ESSDAI Score at Week 24

    ESSDAI measures systemic disease activity in participants with pSjD and consists of 11 organ-specific domains and 1 biological domain that contribute to disease activity level scoring. Each domain is given a certain weight, which gives a score between 0 and 123 (higher score = worse symptoms).

    Time frame: Baseline (Day 1) and Week 24

  8. Change From Baseline in clinESSDAI Score at Week 24

    clinESSDAI includes the same 11 organ-specific domains as ESSDAI but with different domain weighting and without the biological domain. This way any change in clinESSDAI score would reflect disease specific features, irrespective of B-cell activity. The clinESSDAI score ranges between 0-135 (higher score = worse symptoms).

    Time frame: Baseline (Day 1) and Week 24

  9. Change From Baseline in ESSPRI Score at Week 24

    ESSPRI is a questionnaire that has been developed to measure self-reported symptoms in participants with pSjD. The score ranges from 0 (no symptoms) to 10 (more symptoms).

    Time frame: Baseline (Day 1) and Week 24

  10. Percentage of Participants With STAR Score of at Least 5 at Week 24

    Sjögren's Tool for Assessing Response (STAR) is a composite endpoint assessing multiple clinically relevant disease features. A STAR responder is defined as a score of at least 5 points. Due to the weighting, participants must be a responder on either systemic disease activity (ESSDAI), patient-reported symptoms (ESSPRI), or both to be an overall STAR responder. The score ranges between 0 and 9 (higher score = worse outcome).

    Time frame: Week 24

  11. Plasma Concentration of Efgartigimod

    Serum samples were collected at indicated time points to assess the pharmacokinetic (PK) profile of efgartigimod.

    Time frame: Pre-dose at Day 1, Weeks 1, 2, 4, 8, 12, 16, and 20; 30 minutes post-dose at Day 1, Weeks 1, 2, 4, 8, 12, 16, 20 and 24

  12. Percentage Change From Baseline in Total IgG Levels in Serum at Week 24

    Blood samples were collected at indicated timepoints to assess the total Immunoglobulin (Ig)G levels in serum.

    Time frame: Baseline (Day 1) and Week 24

  13. Number of Participants With ADA Against Efgartigimod in Serum

    Blood samples were collected to assess anti-drug antibodies (ADAs) against efgartigimod. Treatment-boosted ADA was defined as participants who had a baseline positive sample and the titer value increased 4-fold or more compared to baseline. Treatment-induced ADA was defined as participants who had a baseline negative sample and at least 1 positive post-baseline samples. Treatment-unaffected ADA was defined as participants who had a baseline positive sample, but the titer value did not increase 4-fold or more compared to baseline.

    Time frame: Up to Week 24

07

Results

Posted Jul 18, 2025

Participant flow

This Phase 2, double-blinded study was conducted in adult participants with primary Sjögren's disease (pSjD) at 15 investigational sites in 3 countries (Belgium, Hungary, and Poland) between 08-May-2023 and 12-Feb-2024.

Participant flow — Overall Study
MilestoneEfgartigimodPlacebo
Started2311
Completed207
Not completed34
Withdrew: Prohibited medication used12
Withdrew: Adverse event10
Withdrew: Withdrawal by subject12

Outcome measures

PrimaryPercentage of Participants Meeting Overall CRESS Response of at Least 3 of 5 Items at Week 24

A Composite of Relevant Endpoints for Sjögren's Syndrome (CRESS) responder is defined as improvements in at least 3 of the 5 items of CRESS (systemic disease activity, patient-reported symptoms, tear gland function, salivary gland function and serology. The score ranges from 0 to 9 (higher score = worse symptoms).

Time frame:
Week 24
Reported as:
Number · Percentage of participants
Percentage of Participants Meeting Overall CRESS Response of at Least 3 of 5 Items at Week 24
Percentage of participantsEfgartigimodPlacebo
Percentage of Participants Meeting Overall CRESS Response of at Least 3 of 5 Items at Week 2445.5 (26.92 to 65.34)11.1 (1.99 to 43.50)
SecondaryNumber of Participants With TEAEs, AESI, and SAEs

A treatment-emergent adverse event (TEAE): adverse events reported from the first dose up to and including 60 days after the final dose were considered treatment-emergent. Serious adverse event (SAE): adverse event that resulted in death, was life threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect or other situations. Adverse event of special interest (AESI): adverse event related to 'Infections and infestations'.

Time frame:
Up to 32 weeks
Reported as:
Count of participants · Participants
Number of Participants With TEAEs, AESI, and SAEs
ParticipantsEfgartigimodPlacebo
Any TEAE207
Any AESI155
Any SAE10
SecondaryPercentage of Participants With MCII in ESSDAI at Week 24

European Alliance of Associations for Rheumatology (EULAR) Sjögren's Syndrome Disease Activity Index (ESSDAI) measures systemic disease activity in participants with pSjD and consists of 11 organ-specific domains and 1 biological domain that contribute to disease activity level scoring. Each domain is given a certain weight, which gives a score between 0 and 123 (higher score =worse symptoms). Minimally clinically important improvement (MCII) in ESSDAI was defined as improvement of at least 3 points in ESSDAI score at Week 24.

Time frame:
Week 24
Reported as:
Number · Percentage of participants
Percentage of Participants With MCII in ESSDAI at Week 24
Percentage of participantsEfgartigimodPlacebo
Percentage of Participants With MCII in ESSDAI at Week 2472.7 (51.85 to 86.85)55.6 (26.67 to 81.12)
SecondaryPercentage of Participants With Low Disease Activity in ESSDAI at Week 24

ESSDAI measures systemic disease activity in participants with pSjD and consists of 11 organ-specific domains and 1 biological domain that contribute to disease activity level scoring. Each domain is given a certain weight, which gives a score between 0 and 123 (higher score =worse symptoms). Low disease activity in ESSDAI was defined as ESSDAI score of less than 5 at Week 24.

Time frame:
Week 24
Reported as:
Number · Percentage of participants
Percentage of Participants With Low Disease Activity in ESSDAI at Week 24
Percentage of participantsEfgartigimodPlacebo
Percentage of Participants With Low Disease Activity in ESSDAI at Week 2459.1 (38.73 to 76.74)22.2 (6.32 to 54.74)
SecondaryPercentage of Participants With MCII in clinESSDAI at Week 24

Clinical (clin)ESSDAI includes the same 11 organ-specific domains as ESSDAI but with different domain weighting and without the biological domain. This way any change in clinESSDAI score would reflect disease specific features, irrespective of B-cell activity. The clinESSDAI score ranges between 0-135 (higher score = worse symptoms). Minimal clinically important improvement (MCII) in clinESSDAI was defined as improvement of at least 3 points in clinESSDAI score at Week 24.

Time frame:
Week 24
Reported as:
Number · Percentage of participants
Percentage of Participants With MCII in clinESSDAI at Week 24
Percentage of participantsEfgartigimodPlacebo
Percentage of Participants With MCII in clinESSDAI at Week 2477.3 (56.56 to 89.88)77.8 (45.26 to 93.68)
SecondaryPercentage of Participants With Low Disease Activity in clinESSDAI at Week 24

clinESSDAI includes the same 11 organ-specific domains as ESSDAI but with different domain weighting and without the biological domain. This way any change in clinESSDAI score would reflect disease specific features, irrespective of B-cell activity. The clinESSDAI score ranges between 0-135 (higher score = worse symptoms). Low disease activity in clinESSDAI was defined as clinESSDAI score of less than 5 at Week 24.

Time frame:
Week 24
Reported as:
Number · Percentage of participants
Percentage of Participants With Low Disease Activity in clinESSDAI at Week 24
Percentage of participantsEfgartigimodPlacebo
Percentage of Participants With Low Disease Activity in clinESSDAI at Week 2459.1 (38.73 to 76.74)33.3 (12.06 to 64.58)
SecondaryPercentage of Participants With MCII in ESSPRI at Week 24

Minimal clinically important improvement in ESSPRI was defined as decrease of 1 point or at least ≥15% at Week 24. ESSPRI is a questionnaire that has been developed to measure self-reported symptoms in participants with pSjD. The score ranges from 0 (no symptoms) to 10 (more symptoms).

Time frame:
Week 24
Reported as:
Number · Percentage of participants
Percentage of Participants With MCII in ESSPRI at Week 24
Percentage of participantsEfgartigimodPlacebo
Percentage of Participants With MCII in ESSPRI at Week 2431.8 (16.36 to 52.68)33.3 (12.06 to 64.58)
SecondaryChange From Baseline in ESSDAI Score at Week 24

ESSDAI measures systemic disease activity in participants with pSjD and consists of 11 organ-specific domains and 1 biological domain that contribute to disease activity level scoring. Each domain is given a certain weight, which gives a score between 0 and 123 (higher score = worse symptoms).

Time frame:
Baseline (Day 1) and Week 24
Reported as:
Median · score on a scale
Change From Baseline in ESSDAI Score at Week 24
score on a scaleEfgartigimodPlacebo
Change From Baseline in ESSDAI Score at Week 24-5.0 (-10.0 to -4.0)-4.0 (-13.0 to -1.0)
SecondaryChange From Baseline in clinESSDAI Score at Week 24

clinESSDAI includes the same 11 organ-specific domains as ESSDAI but with different domain weighting and without the biological domain. This way any change in clinESSDAI score would reflect disease specific features, irrespective of B-cell activity. The clinESSDAI score ranges between 0-135 (higher score = worse symptoms).

Time frame:
Baseline (Day 1) and Week 24
Reported as:
Median · score on a scale
Change From Baseline in clinESSDAI Score at Week 24
score on a scaleEfgartigimodPlacebo
Change From Baseline in clinESSDAI Score at Week 24-7.0 (-12.0 to -3.0)-4.0 (-17.0 to -3.0)
SecondaryChange From Baseline in ESSPRI Score at Week 24

ESSPRI is a questionnaire that has been developed to measure self-reported symptoms in participants with pSjD. The score ranges from 0 (no symptoms) to 10 (more symptoms).

Time frame:
Baseline (Day 1) and Week 24
Reported as:
Median · score on a scale
Change From Baseline in ESSPRI Score at Week 24
score on a scaleEfgartigimodPlacebo
Change From Baseline in ESSPRI Score at Week 24-0.500 (-1.333 to 0.333)-0.833 (-1.333 to -0.333)
SecondaryPercentage of Participants With STAR Score of at Least 5 at Week 24

Sjögren's Tool for Assessing Response (STAR) is a composite endpoint assessing multiple clinically relevant disease features. A STAR responder is defined as a score of at least 5 points. Due to the weighting, participants must be a responder on either systemic disease activity (ESSDAI), patient-reported symptoms (ESSPRI), or both to be an overall STAR responder. The score ranges between 0 and 9 (higher score = worse outcome).

Time frame:
Week 24
Reported as:
Number · Percentage of participants
Percentage of Participants With STAR Score of at Least 5 at Week 24
Percentage of participantsEfgartigimodPlacebo
Percentage of Participants With STAR Score of at Least 5 at Week 2454.5 (34.66 to 73.08)33.3 (12.06 to 64.58)
SecondaryPlasma Concentration of Efgartigimod

Serum samples were collected at indicated time points to assess the pharmacokinetic (PK) profile of efgartigimod.

Time frame:
Pre-dose at Day 1, Weeks 1, 2, 4, 8, 12, 16, and 20; 30 minutes post-dose at Day 1, Weeks 1, 2, 4, 8, 12, 16, 20 and 24
Reported as:
Mean · Nanograms per milliliter (ng/mL)
Plasma Concentration of Efgartigimod
Nanograms per milliliter (ng/mL)Efgartigimod
Day 1: Pre-doseNA ± NA
Day 1: 30 minutes post-dose179391 ± 79751
Week 1: Pre-dose17238 ± 37356
Week 1: 30 minutes post-dose187300 ± 73091
Week 2: Pre-dose22470 ± 42838
Week 2: 30 minutes post-dose205148 ± 52448
Week 4: Pre-dose38595 ± 65900
Week 4: 30 minutes post-dose206414 ± 102089
Week 8: Pre-dose14193 ± 5753
Week 8: 30 minutes post-dose203505 ± 89762
Week 12: Pre-dose13096 ± 4523
Week 12: 30 minutes post-dose200856 ± 138766
Week 16: Pre-dose12676 ± 5835
Week 16: 30 minutes post-dose261647 ± 215940
Week 20: Pre-dose12942 ± 4472
Week 20: 30 minutes post-dose194944 ± 81722
Week 24: 30 minutes post-dose14284 ± 4987
SecondaryPercentage Change From Baseline in Total IgG Levels in Serum at Week 24

Blood samples were collected at indicated timepoints to assess the total Immunoglobulin (Ig)G levels in serum.

Time frame:
Baseline (Day 1) and Week 24
Reported as:
Mean · Percentage change
Percentage Change From Baseline in Total IgG Levels in Serum at Week 24
Percentage changeEfgartigimodPlacebo
Percentage Change From Baseline in Total IgG Levels in Serum at Week 24-57.172 ± 17.73760.279 ± 9.5193
SecondaryNumber of Participants With ADA Against Efgartigimod in Serum

Blood samples were collected to assess anti-drug antibodies (ADAs) against efgartigimod. Treatment-boosted ADA was defined as participants who had a baseline positive sample and the titer value increased 4-fold or more compared to baseline. Treatment-induced ADA was defined as participants who had a baseline negative sample and at least 1 positive post-baseline samples. Treatment-unaffected ADA was defined as participants who had a baseline positive sample, but the titer value did not increase 4-fold or more compared to baseline.

Time frame:
Up to Week 24
Reported as:
Count of participants · Participants
Number of Participants With ADA Against Efgartigimod in Serum
ParticipantsEfgartigimodPlacebo
Treatment-boosted ADA10
Treatment-induced ADA20
Treatment-unaffected ADA113

Adverse events

Collected over Up to 32 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Efgartigimod0/23 (0%)1/23 (4.3%)20/23 (87%)
Placebo0/11 (0%)0/11 (0%)7/11 (63.6%)
Most frequent serious events
Most frequent serious events
EventEfgartigimodPlacebo
VasospasmVascular disorders1/230/11
Most frequent other events
Showing 10 of 30
Most frequent other events
EventEfgartigimodPlacebo
Upper respiratory tract infectionInfections and infestations3/232/11
NasopharyngitisInfections and infestations4/231/11
HeadacheNervous system disorders4/231/11
InfluenzaInfections and infestations3/230/11
Urinary tract infectionInfections and infestations3/231/11
Iron deficiency anaemiaBlood and lymphatic system disorders0/231/11
PalpitationsCardiac disorders0/231/11
Motion sicknessEar and labyrinth disorders0/231/11
Abdominal painGastrointestinal disorders0/231/11
Abdominal pain lowerGastrointestinal disorders0/231/11

Baseline characteristics

Full Analysis Set (FAS) included all randomized participants who received at least 1 dose of study treatment and who were classified according to the planned treatment.

Age, Continuous
Age, Continuous(Years)EfgartigimodPlaceboTotal
Mean50.1 ± 12.5754.7 ± 12.4251.6 ± 12.52
Sex: Female, Male
Sex: Female, Male(Participants)EfgartigimodPlaceboTotal
Female221133
Male101
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)EfgartigimodPlaceboTotal
Hispanic or Latino000
Not Hispanic or Latino221133
Unknown or Not Reported101
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)EfgartigimodPlaceboTotal
White221133
Unknown101
08

Study locations

17 sites
  • Universitair Ziekenhuis Gent
    Ghent, 9000, Belgium
  • Debreceni Egyetem
    Debrecen, 4032, Hungary
  • Vita Verum Medical Egeszsegugyi Szolgaltato Bt.
    Székesfehérvár, 8000, Hungary
  • Universitair Medisch Centrum Groningen , Dept of Rheumatology and Clinical Immunology
    Groningen, 9713 GZ, Netherlands
  • Ambulatorium Barbara Bazela
    Elblag, 82-300, Poland
  • MCBK Iwona Czajkowska Anna Podrażka- Szczepaniak S.C.
    Grodzisk Mazowiecki, 05-825, Poland
  • Centrum Medyczne Plejady
    Krakow, 30-363, Poland
  • FutureMeds Krakow
    Krakow, 31-501, Poland
  • ETG Lublin
    Lublin, 20-412, Poland
  • Reumed Spolka z o.o.
    Lublin, 20-607, Poland
  • Clinical Research Center Spółka z ograniczoną odpowiedzialnością Medic-R Sp.k.
    Poznan, 60-848, Poland
  • Centrum Medyczne Pratia Poznan
    Skórzewo, 60-185, Poland
  • MICS Centrum Medyczne Warszawa
    Warsaw, 00-874, Poland
  • KO-Med - Centrum Badań Medycznych NIGRiR
    Warsaw, 02-637, Poland
  • Centrum Medyczne Reuma Park
    Warsaw, 02-691, Poland
  • FutureMeds Targowek
    Warsaw, 03-291, Poland
  • FutureMeds Wroclaw
    Wroclaw, 50-088, Poland
09

References and documents

Publications

  • Peene I, Verstappen GM, Arends S, Kroese FGM, De Boeck K, Achten H, Papadopoulou D, Jacobs J, Bowen E, Teperov E, Meyvisch P, Fardipour P, Kelly A, Brahmbhatt J, Elewaut D, Bootsma H. Efgartigimod in Sjogren's disease: a phase 2, randomised, placebo-controlled, parallel-group, double-blinded, proof-of-concept study (RHO). Ann Rheum Dis. 2026 Apr 16:S0003-4967(26)00205-0. doi: 10.1016/j.ard.2026.03.019. Online ahead of print. PubMed 41997805 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2023 to primary completion in Jan 2024, 9 months.

Results were first posted in Jul 2025, 1 year 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 1, 2023
First posted
Apr 18, 2023
StartActual
Apr 4, 2023
Primary completionActual
Jan 29, 2024
CompletionActual
Feb 12, 2024
Results first posted
Jul 18, 2025
Last update
Jul 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05817669
Lead sponsor
argenx
Collaborators
IQVIA Pty Ltd
Responsible party
Sponsor
First posted
Apr 18, 2023
Start date
Apr 4, 2023
Primary completion
Jan 29, 2024
Completion
Feb 12, 2024
Results posted
Jul 18, 2025
Last update
Jul 18, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Efgartigimod alfa

Start the discussion